上市後觀察性登記探討INLYTA®用於治療台灣晚期腎細胞癌患者的使用劑量、安全性及效益

主要目的為觀察INLYTA®在實際臨床治療上，用於晚期腎細胞癌時的劑量變化。
次要目的為觀察INLYTA®在實際臨床治療上的安全性、客觀有效率以及疾病無惡化率。

6

起始日期：Dec. 1, 2015　預計結束日期：Dec. 31, 2017

NA, Given this is a registry rather than a clinical research of comparison, the sample size is limited by actual patients fulfill the inclusion criteria and without any situation listed in exclusion criteria treated in Taiwan during the registry period; a calculated sample number is not applicable for present setting.人

Nov.3, 2015

Dec. 31, 2018